Erste Group Bank Has Negative View of AbbVie FY2027 Earnings

Key Points

• Erste Group Bank lowered its FY2027 EPS forecast for AbbVie to $16.28 from $16.34, while maintaining a “Buy” rating. The estimate remains above the current full-year consensus of $13.93.
• AbbVie’s latest quarter exceeded expectations, with adjusted EPS of $3.65 versus the $3.61 consensus and revenue of $16.99 billion, up 10.2% year over year. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• Analyst sentiment remains broadly positive: AbbVie has a consensus “Moderate Buy” rating and an average price target of $279.86, while the company continues to offer a quarterly dividend of $1.73 per share, equivalent to a 2.4% yield.

AbbVie Inc. (NYSE:ABBV - Free Report) - Erste Group Bank cut their FY2027 earnings per share estimates for shares of AbbVie in a report issued on Wednesday, October 21st. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $16.28 per share for the year, down from their previous forecast of $16.34. Erste Group Bank has a "Buy" rating on the stock. The consensus estimate for AbbVie's current full-year earnings is $13.93 per share.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the business earned $2.97 EPS. The firm's revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS.

ABBV has been the topic of several other reports. Piper Sandler boosted their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. Scotiabank upped their price objective on shares of AbbVie from $280.00 to $320.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 6th. Cantor Fitzgerald raised their target price on shares of AbbVie from $285.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, October 8th. Wall Street Zen downgraded shares of AbbVie from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 5th. Finally, Citigroup lifted their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $279.86.

AbbVie Price Performance

Shares of NYSE ABBV opened at $285.66 on Monday. The stock has a fifty day moving average price of $266.33 and a 200 day moving average price of $242.01. AbbVie has a 1-year low of $190.75 and a 1-year high of $291.40. The company has a market cap of $504.70 billion, a PE ratio of 80.69, a P/E/G ratio of 1.30 and a beta of 0.24.

Institutional Investors Weigh In On AbbVie

Institutional investors have recently modified their holdings of the company. Burk Holdings LLC purchased a new stake in AbbVie during the second quarter worth $30,000. Marquette Asset Management LLC grew its holdings in AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock valued at $35,000 after purchasing an additional 48 shares during the last quarter. Principia Wealth Advisory LLC grew its holdings in AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Merkkuri Wealth Advisors LLC purchased a new position in shares of AbbVie in the first quarter valued at $34,000. Finally, IMG Wealth Management Inc. increased its position in shares of AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock valued at $40,000 after buying an additional 153 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie's dividend payout ratio is 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.